SEC Filing Summary
Entity note: The request identifies Viridian Therapeutics, Inc., but the supplied Form 10-K is for Miragen Therapeutics, Inc. (Nasdaq: MGEN). The filing does not identify Viridian as the registrant.
Business Context and Reporting Period
This is Miragen’s annual report for the fiscal year ended December 31, 2019, filed March 13, 2020. The company was a clinical-stage biopharmaceutical developer of microRNA-targeted therapies, with no approved products and no product-sale revenue. The filing also provides unaudited quarterly results, including fourth-quarter 2019.
Key programs were cobomarsen for miR-155-associated cancers, including cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL); remlarsen and MRG-229 for fibrosis; and MRG-110 for wound healing, heart failure, and other ischemic conditions.
Financial Results and Liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $4.461 million | $8.386 million |
| Research and development expense | $34.794 million | $30.421 million |
| General and administrative expense | $11.646 million | $11.049 million |
| Operating loss | $41.979 million | $33.084 million |
| Net loss | $41.873 million | $32.703 million |
| Net loss per share, basic and diluted | $1.34 | $1.10 |
| Net cash used in operating activities | $36.056 million | $26.844 million |
Revenue consisted principally of Servier collaboration reimbursements and grant revenue, not product sales. Revenue declined mainly because a $3.690 million Servier milestone recognized in 2018 did not recur, alongside lower grant revenue. The operating loss was approximately 9.4 times revenue; this is not a product gross margin, as the company had no product sales.
At December 31, 2019, cash and cash equivalents were $24.846 million and short-term investments were $1.999 million, totaling $26.845 million. Current assets were $29.739 million and current liabilities $10.180 million. Note payable principal was $7.667 million ($8.304 million carrying amount, including the accreted final payment fee and debt discount); $3.976 million was classified as current. No additional borrowing was available under the facility.
Cash and cash equivalents declined $7.760 million during 2019. Investing activities provided $28.226 million, largely reflecting maturities of short-term investments; financing activities provided $0.070 million. The filing reports no material commitments beyond recorded liabilities and disclosed commitments, and no off-balance-sheet arrangements.
Fourth-quarter 2019: Revenue was $0.880 million, R&D expense $8.417 million, G&A expense $2.534 million, net loss $10.118 million, and net loss per share $0.31. Fourth-quarter 2018 net loss was $10.317 million on revenue of $0.476 million.
Material Changes Versus Prior Period
- Annual revenue fell to $4.461 million from $8.386 million; R&D expense rose $4.373 million, primarily with cobomarsen clinical and manufacturing activity and personnel-related costs.
- Net loss widened to $41.873 million from $32.703 million, and operating cash use increased by $9.212 million.
- In December 2019, Miragen stopped enrolling new patients in the Phase 2 SOLAR CTCL trial after 37 patients enrolled, and changed the planned analysis to focus on durable skin response versus vorinostat. The company said the smaller cohort would not support its previously contemplated accelerated-approval path.
- Servier gave notice of termination in August 2019; the collaboration ended in February 2020. Miragen regained global rights to MRG-110, but future development would depend on available capital and potentially a new collaborator.
- A 2019 restructuring identified approximately 44 positions for elimination, about half the workforce. The company recorded approximately $2.0 million of restructuring expense and expected another $0.2 million in the first half of 2020.
Outlook, Commentary, and Principal Risks
Management expected available resources, including post-year-end equity proceeds received through the filing date, to fund operations into the third quarter of 2021. Additional capital would be required thereafter, and the company warned that failure to raise funding could force delays, reductions, or termination of programs or operations. Management did not conclude that substantial doubt existed as of December 31, 2019, but stated that future funding remained necessary.
- Post-year-end financing included a February 2020 public offering of 15 million shares and warrants for 7.5 million shares, producing approximately $14.0 million in net proceeds, excluding any warrant exercise proceeds. Aspire Capital share sales also generated $4.1 million in January 2020. These financings involved dilution; the warrants have an exercise price of $1.10 per share.
- Management expected 2020 milestones including CTCL topline data and an FDA meeting regarding a potential expedited ATLL development path in Q3, remlarsen Phase 2 primary-endpoint data in the second half, and additional MRG-229 preclinical data in Q2. These are forward-looking targets, not completed events.
- Interim remlarsen keloid-trial data were described as generally safe and well tolerated, with no reported negative effect on healing and initial volume reductions in a subset of treated patients; the company planned to await the one-year endpoint.
- January 2020 interim ATLL results covered six patients. The filing described disease stabilization and biomarker changes, while noting one patient had two serious adverse events considered possibly related to cobomarsen and discontinued treatment. The small, early-stage dataset does not establish efficacy.
- Key risks include clinical failure or delay, uncertain safety and efficacy of a novel microRNA approach, dependence on third-party manufacturers and clinical vendors, limited funding and potential further dilution, loss of collaboration support, and competition and reimbursement uncertainty. The filing also identified possible COVID-19-related disruption to trials and supply chains.
- Nasdaq had notified the company in October 2019 that its share price was below the $1.00 minimum bid-price requirement; the stated initial compliance deadline was April 27, 2020. The filing also states the company ceased to qualify as an emerging growth company beginning January 1, 2020.
Most Important Facts for Investors to Verify
- Confirm the issuer: this filing is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Check subsequent filings for actual SOLAR trial results, further CTCL development plans, and the FDA’s response to the proposed ATLL pathway.
- Verify cash runway against actual spending, debt service, subsequent financing, and any later capital raises or collaborations.
- Review the full audited financial statements and debt terms, including scheduled principal payments and covenants.
- Track whether remlarsen and MRG-229 data support progression, and whether MRG-110 advances following Servier’s termination.
- Check subsequent disclosures on Nasdaq listing compliance, COVID-19 effects, and dilution from share issuance or warrant exercises.